Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics Inc (ARQT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 982,769
  • Shares Outstanding, K 60,928
  • Annual Sales, $ 0 K
  • Annual Income, $ -206,360 K
  • 60-Month Beta 0.48
  • Price/Sales 1,164.13
  • Price/Cash Flow N/A
  • Price/Book 3.05
Trade ARQT with:

Options Overview Details

View History
  • Implied Volatility 65.59% ( -10.12%)
  • Historical Volatility 55.46%
  • IV Percentile 10%
  • IV Rank 26.85%
  • IV High 139.98% on 03/11/22
  • IV Low 38.28% on 12/08/22
  • Put/Call Vol Ratio 1.43
  • Today's Volume 34
  • Volume Avg (30-Day) 157
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 7,656
  • Open Int (30-Day) 8,380

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -1.37
  • Number of Estimates 2
  • High Estimate -1.36
  • Low Estimate -1.38
  • Prior Year -1.42
  • Growth Rate Est. (year over year) +3.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.81 +25.68%
on 01/12/23
16.85 -4.45%
on 01/23/23
+1.80 (+12.59%)
since 12/23/22
3-Month
12.81 +25.68%
on 01/12/23
20.11 -19.94%
on 11/15/22
-0.52 (-3.13%)
since 10/26/22
52-Week
12.81 +25.68%
on 01/12/23
27.40 -41.24%
on 08/31/22
+1.02 (+6.76%)
since 01/26/22

Most Recent Stories

More News
MyHealthTeam and Arcutis Biotherapeutics Launch New Social Network for People Living with Seborrheic Dermatitis

/PRNewswire/ -- MyHealthTeam, creator of the largest and fastest-growing social networks for people living with chronic health conditions, today launched...

ARQT : 16.10 (-0.19%)
Arcutis (ARQT) Up on Top-Line Data From Atopic Dermatitis Study

Arcutis Biotherapeutics (ARQT) reports positive top-line data from a phase III study of its lead candidate, roflumilast cream 0.15%, for treating atopic dermatitis.

AVEO : 15.00 (unch)
ETON : 3.64 (unch)
ARQT : 16.10 (-0.19%)
IMCR : 60.67 (+1.76%)
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Misses Revenue Estimates

Arcutis Biotherapeutics, Inc. (ARQT) delivered earnings and revenue surprises of -22.73% and 27.86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for...

ARQT : 16.10 (-0.19%)
ANGN : 0.6960 (+8.70%)
LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million

/PRNewswire/ -- LifeArc today announced that its portfolio company DucentisBioTherapeutics, a preclinical-stage biotechnology company focused on developing...

ARQT : 16.10 (-0.19%)
NEW CAMPAIGN FROM ARCUTIS AIMS TO EXPOSE THE IMPACT OF PSORIASIS ON PHYSICAL, MENTAL, AND EMOTIONAL WELLBEING

/PRNewswire/ -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) today announced the launch of an educational campaign designed to raise awareness about the...

ARQT : 16.10 (-0.19%)
Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and AVEO Pharmaceuticals (AVEO) have performed compared to their sector so far this year.

ARQT : 16.10 (-0.19%)
AVEO : 15.00 (unch)
Wall Street Analysts Believe Arcutis Biotherapeutics, Inc. (ARQT) Could Rally 134%: Here's is How to Trade

The mean of analysts' price targets for Arcutis Biotherapeutics, Inc. (ARQT) points to a 134.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

ARQT : 16.10 (-0.19%)
Is Albireo Pharma (ALBO) Outperforming Other Medical Stocks This Year?

Here is how Albireo Pharma (ALBO) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

ALBO : 43.95 (+0.11%)
ARQT : 16.10 (-0.19%)
Can Arcutis Biotherapeutics, Inc. (ARQT) Climb 123% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Arcutis Biotherapeutics, Inc. (ARQT) points to a 122.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

ARQT : 16.10 (-0.19%)
Arcutis Launches ZORYVE™ (Roflumilast) Cream 0.3% in the United States for Treatment of Plaque Psoriasis in Individuals Age 12 and Older

Next-generation topical PDE4 inhibitor for adults and adolescents with plaque psoriasis now available in pharmacies nationwideEffective, safe, and very...

ARQT : 16.10 (-0.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis,...

See More

Key Turning Points

3rd Resistance Point 16.97
2nd Resistance Point 16.55
1st Resistance Point 16.34
Last Price 16.10
1st Support Level 15.71
2nd Support Level 15.29
3rd Support Level 15.08

See More

52-Week High 27.40
Fibonacci 61.8% 21.83
Fibonacci 50% 20.10
Fibonacci 38.2% 18.38
Last Price 16.10
52-Week Low 12.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar